IMMUNOVANT, INC. Research and Development Asset Acquired Other than Through Business Combination, Written-off
IMMUNOVANT, INC. (IMVT) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $0 for the 12-month period ending 2026-03-31, per its 10-K filed 2026-05-20.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2026-05-20
- IMMUNOVANT, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2025-03-31 was $0.00.
- IMMUNOVANT, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2024-12-31 was $0.00.
- IMMUNOVANT, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2024-09-30 was $0.00.
- IMMUNOVANT, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- IMMUNOVANT, INC. research and development asset acquired other than through business combination, written-off for fiscal 2026 was $0.00.
- IMMUNOVANT, INC. research and development asset acquired other than through business combination, written-off for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- IMMUNOVANT, INC. research and development asset acquired other than through business combination, written-off for fiscal 2024 was $12.50M, a 25.00% increase from fiscal 2023.
- IMMUNOVANT, INC. research and development asset acquired other than through business combination, written-off for fiscal 2023 was $10.00M.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|---|---|---|
| 2026-03-31 | $0.00 10-K · filed 2026-05-20 | |||
| 2025-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $0.00 derived: sum of 2 quarters · filed 2026-05-20 | $0.00 derived: sum of 3 quarters · filed 2026-05-20 | $0.00 10-K · filed 2026-05-20 |
| 2024-12-31 | $0.00 10-Q · filed 2025-02-06 | $0.00 derived: sum of 2 quarters · filed 2025-02-06 | $0.00 10-Q · filed 2025-02-06 | $0.00 derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 3 quarters · filed 2026-05-20 | $0.00 derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-06 | $0.00 derived: sum of 2 quarters · filed 2026-05-20 | $0.00 derived: sum of 3 quarters · filed 2026-05-20 | $0.00 derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $0.00 derived: sum of 2 quarters · filed 2026-05-20 | $0.00 derived: sum of 3 quarters · filed 2026-05-20 | $12.50M 10-K · filed 2026-05-20 |
| 2023-12-31 | $0.00 10-Q · filed 2025-02-06 | $0.00 derived: sum of 2 quarters · filed 2025-02-06 | $12.50M 10-Q · filed 2025-02-06 | $12.50M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 | $12.50M 10-Q · filed 2024-11-07 | $12.50M derived: sum of 3 quarters · filed 2025-05-29 | $22.50M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-06-30 | $12.50M 10-Q · filed 2024-08-06 | $12.50M derived: sum of 2 quarters · filed 2025-05-29 | $22.50M derived: sum of 3 quarters · filed 2025-05-29 | $22.50M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29 | $10.00M derived: sum of 2 quarters · filed 2025-05-29 | $10.00M derived: sum of 3 quarters · filed 2025-05-29 | $10.00M 10-K · filed 2025-05-29 |
| 2022-12-31 | $10.00M 10-Q · filed 2024-02-12 | $10.00M derived: sum of 2 quarters · filed 2024-02-12 | $10.00M 10-Q · filed 2024-02-12 | |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |